Education
About Us
Working with TipRanks
Follow Us
Biotricity Inc (BTCY)
OTHER OTC:BTCY
BTCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.19 - $1.65
Previous CloseN/A
Volume50.15K
Average Volume (3M)42.95K
Market Cap
$11.80M
Enterprise Value$30.41M
Total Cash (Recent Filing)$509.60K
Total Debt (Recent Filing)$12.86M
Price to Earnings (P/E)―
Beta-1.56
Next Earnings
Jun 27, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding24,751,757
10 Day Avg. Volume31,880
30 Day Avg. Volume42,945
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.89
Price to Cash Flow (P/CF)-33.50
P/FCF Ratio3.60
Enterprise Value/Market Cap2.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda-5.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Biotricity News
PremiumCompany Announcements
Biotricity Reports Revenue Growth Amidst Financial Challenges
PremiumCompany Announcements
Biotricity Notifies Delay in Quarterly Report Filing
PremiumCompany Announcements
Biotricity Reports Revenue Growth Amidst Ongoing Losses
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBiotricity reported a doubling of free cash flow compared to FY2Q25 on an 11% increase in sales to $3.6M.
Patent AcquisitionPatent acquisition enhances Biotricity’s competitive profile in multi-sensor monitoring.
Strategic PartnershipsStrategic agreements with leading group purchasing organizations have opened access to over 90% of U.S. hospitals, creating opportunities for larger-scale adoption.
Bears Say
Investment RisksInvestment in Biotricity carries risks common to small-cap companies, such as dilution and competition.
Sales ProjectionAdjustment to estimates with a lower FY25 sales projection indicates caution about the company's immediate financial performance.
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.19% Other Institutional Investors
99.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BTCY FAQ
What was Biotricity Inc’s price range in the past 12 months?
Biotricity Inc lowest stock price was $0.19 and its highest was $1.65 in the past 12 months.
What is Biotricity Inc’s market cap?
Biotricity Inc’s market cap is $11.80M.
When is Biotricity Inc’s upcoming earnings report date?
Biotricity Inc’s upcoming earnings report date is Jun 27, 2025 which is in 93 days.
How were Biotricity Inc’s earnings last quarter?
Biotricity Inc released its earnings results on Feb 20, 2025. The company reported -$0.054 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.056.
Is Biotricity Inc overvalued?
According to Wall Street analysts Biotricity Inc’s price is currently Overvalued.
Does Biotricity Inc pay dividends?
Biotricity Inc does not currently pay dividends.
What is Biotricity Inc’s EPS estimate?
Biotricity Inc’s EPS estimate is -0.1.
How many shares outstanding does Biotricity Inc have?
Biotricity Inc has 24,751,757 shares outstanding.
What happened to Biotricity Inc’s price movement after its last earnings report?
Biotricity Inc reported an EPS of -$0.054 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Biotricity Inc?
Currently, no hedge funds are holding shares in BTCY
---
Company Description
Biotricity Inc
Biotricity, Inc. engages in the provision of biometric data monitoring solutions. The firm offers the Bioflux, a single-unit mobile cardiac telemetry device. It also develops Biolife, which is intended for chronic disease prevention. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.
---
BTCY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a predominantly positive outlook with significant achievements in EBITDA, revenue growth, strategic partnerships, and market expansion. Despite the continued net loss, the improvements and strategic advancements position Biotricity well for future profitability.Read More>---
BTCY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---